Индекс атерогенности (коэффициент атерогенности)

The Lipid panel with cardiovascular risk assessment by high-sensitivity troponin I combines a standard lipid profile with hs‑troponin I to estimate future cardiovascular risk in both asymptomatic adults and individuals with established cardiometabolic disease. By integrating total cholesterol and its fractions with triglycerides and a cardiac‑specific injury marker, the assay supports baseline risk stratification, longitudinal follow‑up, and treatment planning. This test—also referenced as a lipid profile, coronary risk panel, or hs‑TnI assessment—assists in evaluating persons with familial hypercholesterolemia or a strong family history of cardiovascular events, monitoring response to lipid‑lowering and antihypertensive therapy (including statins and diet), and informing preoperative cardiovascular risk assessment before noncardiac surgery.

A lipid profile evaluates triglycerides along with total cholesterol and its fractions—high‑density lipoprotein (HDL‑C), low‑density lipoprotein (LDL‑C), and very‑low‑density lipoprotein (VLDL‑C)—to characterize disordered lipid metabolism and estimate atherosclerotic risk. The atherogenic index, calculated as (total cholesterol − HDL‑C) / HDL‑C, increases with higher total cholesterol, LDL‑C, VLDL‑C, and triglycerides and with lower HDL‑C; values above 3 are consistent with elevated atherogenic risk. High‑sensitivity cardiac troponin I (hs‑TnI) is a sensitive and specific indicator of myocardial injury classically used in acute coronary syndromes. Beyond acute presentations, repeated population‑based studies demonstrate prognostic utility of hs‑TnI for future cardiovascular events—including myocardial infarction, heart failure, ischemic stroke, coronary revascularization, and cardiovascular mortality—even among individuals without symptoms. Risk appears higher in apparently healthy persons whose troponin I concentrations approach the upper reference limit. Cardiovascular disease remains a leading global cause of death, and prevention strategies emphasize accurate risk prediction. Incorporating hs‑TnI into customary risk algorithms such as SCORE or the Framingham model can refine patient reclassification and improve risk discrimination. Troponin I provides prognostic information independent of LDL‑cholesterol lowering, supporting its adjunctive role alongside traditional lipid metrics in estimating cardiovascular risk.